TScan Therapeutics, Inc. - TCRX STOCK NEWS

TScan Therapeutics (NASDAQ: TCRX) presented updated results from their ALLOHA™ Phase 1 trial of TSC-100 and TSC-101, treatments designed to prevent relapse in patients with AML, ALL, and MDS post-transplant. The trial enrolled 38 patients (26 treatment, 12 control).

Key findings show significantly better event-free survival in the treatment arm (HR=0.30; p=0.04) with lower relapse rates (8% vs 33% in control). No dose-limiting toxicities were observed, and treatments were well-tolerated across all dose levels. Notably, among patients with TP53 mutations, none of the 4 treated patients relapsed, while both control patients relapsed within 6 months.

Based on these results, the company plans to launch a pivotal trial in the second half of 2025.

TScan Therapeutics (Nasdaq: TCRX) has been recognized as one of the Top Places to Work in Massachusetts by The Boston Globe for the third consecutive year. The recognition is based on an employee survey conducted by Energage, involving nearly 68,000 employees across 323 Massachusetts organizations. The survey evaluates various aspects including company direction, execution, management, work environment, compensation, and employee engagement.

The company, which focuses on developing TCR-engineered T cell therapies for cancer treatment, was evaluated among different workplace categories based on employee count. CEO Gavin MacBeath highlighted the company's commitment to advancing their clinical-stage pipeline for heme malignancies and solid tumors, while SVP of Human Resources Ann Hargraves emphasized the organization's growth and culture development over the past five years.

TScan Therapeutics (Nasdaq: TCRX) announces a virtual KOL event to discuss data from their ALLOHA™ Phase 1 heme trial presented at the ASH Annual Meeting and their clinical development strategy. The event, scheduled for December 10 at 8:00 a.m. ET, will review preliminary results of TSC-100 and TSC-101 in patients with AML, ALL, and MDS undergoing allogeneic hematopoietic cell transplantation. The company will also provide updates on their PLEXI-T™ Phase 1 solid tumor trial and discuss potential registrational pathways following their FDA meeting.

TScan Therapeutics (NASDAQ: TCRX) reported Q3 2024 financial results with revenue of $1.0 million, down from $3.9 million in Q3 2023. Net loss widened to $29.9 million from $23.0 million year-over-year. R&D expenses increased to $26.3 million, while G&A expenses rose to $7.4 million.

The company's ALLOHA Phase 1 trial showed promising results with no relapses in 16 treatment-arm patients, including five patients at one-year post-transplant. Cash position stands at $271.1 million, expected to fund operations into Q4 2026. TScan plans to present updated trial data at the upcoming ASH Annual Meeting and remains on track to dose its first patient with multiplex TCR-T therapy.

TScan Therapeutics (NASDAQ: TCRX) announced preliminary results from the ALLOHA™ Phase 1 trial of TSC-100 and TSC-101 for blood cancers. The trial enrolled 27 patients, with 16 in the treatment arm and 11 in the control arm. Key findings showed no relapses in the treatment arm versus three relapses in the control arm, with a median time to relapse of 159 days in the control group. All five TSC-treated patients reaching one-year follow-up remained relapse-free and MRD negative. No dose-limiting toxicities were reported, and safety profiles were similar between treatment and control arms.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houston, TX and virtually.

The presentations include:

• Discovery of a MAGE-A4-specific TCR-T Therapy Candidate for Multiplex Treatment of Solid Tumors
• Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Heterogeneity
• Development of a Target Agnostic Platform to Assess the Reactivity of TCR-T Therapies to Primary Human Tissues

All presentations will take place in the Exhibit Halls AB at the George R. Brown Convention Center. The presentation materials will be available on TScan's website after the event concludes.

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment, has announced its participation in two upcoming investor conferences:

1. Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on September 5, 2024, at 8:30 a.m. ET at the New York Marriott Marquis.

2. H.C. Wainwright 26th Annual Global Investment Conference: Presentation on September 10, 2024, at 9:00 a.m. ET at the Lotte New York Palace Hotel.

Webcasts of both events will be available on TScan's website under the "Events and Presentations" section, with archived replays accessible for 90 days post-event.

TScan Therapeutics (Nasdaq: TCRX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:

1. FDA granted RMAT designation to TSC-100 and TSC-101 for treating AML, ALL, and MDS patients undergoing allogeneic HCT.

2. Engaged a global CDMO for pivotal trials and commercialization manufacturing support.

3. On track to report initial solid tumor program data and one-year ALLOHA Phase 1 heme trial data by end of 2024.

4. Cash position of $297.7 million, funding operations into Q4 2026.

5. Q2 2024 revenue: $0.5 million; R&D expenses: $26.9 million; G&A expenses: $7.8 million; Net loss: $31.7 million.

6. Anticipating expansion cohorts opening in Q3 2024 and initiation of a registration trial in 2025.

TScan Therapeutics, a clinical-stage biopharmaceutical company, announced changes to its Board of Directors. Garry A. Nicholson, an executive with extensive regulatory and commercial expertise, has joined the board. Timothy Barberich has retired as Chair, and Stephen Biggar, M.D., Ph.D., a current board member, will assume the role of Chair. CEO Gavin MacBeath highlighted Nicholson's 35+ years of oncology experience, including his tenure as president of Pfizer Oncology. Nicholson will support TScan’s mission to advance T cell receptor-engineered therapies for cancer. Barberich, who joined the board in 2019 and served as Chair since 2021, was acknowledged for his contributions. Biggar, a board member since 2021, steps into the leadership role. Nicholson's background includes leadership roles at Pfizer, Eli Lilly, and XTuit Pharmaceuticals, as well as board positions at several biotech companies.